Skip to content

Study · Animal study (in vivo) · cynomolgus monkey · 2019

3 results

TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias.

Breinholt VM, Rasmussen CE, Mygind PH, Kjelgaard-Hansen M, Faltinger F, Bernhard A, Zettler J, Hersel U

The Journal of pharmacology and experimental therapeutics24 Jun 2019Cited by 48 (Europe PMC)

PMID31235532 (opens in a new tab)DOI10.1124/jpet.119.258251 (opens in a new tab)PepBankPUB-31235532
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In cynomolgus monkeys, CNP-39 had an estimated half-life of 20 minutes versus 90 hours for CNP-38 released from TransCon CNP.

    In plain wordsIn cynomolgus monkeys, CNP-39 had a half-life of 20 minutes versus 90 hours for CNP-38 released from TransCon CNP.

    Peptide
    Vosoritide
    Outcome
    DecreaseHalf-life
    Study

    cynomolgus monkeyn: not reported in source

    Comparator
    CNP-38 released from TransCon CNP
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    The half-life of the daily CNP-39 molecule in cynomolgus monkey was estimated to be 20 minutes, compared with 90 hours for CNP-38, released from TransCon CNP.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In animal studies, CNP-39 peak concentration at 20 µg/kg was approximately 100-fold higher than after 100 µg/kg CNP as TransCon CNP.

    In plain wordsIn animals, CNP-39 peak concentration at 20 µg/kg was approximately 100-fold higher than after 100 µg/kg CNP as TransCon CNP.

    Peptide
    Vosoritide
    Outcome
    IncreasePeak concentration
    Study

    n: not reported in source

    Comparator
    CNP-38 released from TransCon CNP
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 µg/kg · subcutaneousAs given in this study.

    Source sentences

    Summary
    C max for the CNP-39 molecule (20 µg/kg) was approximately 100-fold higher, compared with the peak CNP level associated with administration of 100 µg/kg CNP as TransCon CNP.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In animal studies, CNP-39 exposure was evident for up to 2 hours versus at least 7 days for CNP-38 after TransCon CNP.

    In plain wordsIn animals, CNP-39 exposure lasted up to 2 hours versus at least 7 days for CNP-38 after TransCon CNP.

    Peptide
    Vosoritide
    Outcome
    DecreaseDuration of systemic exposure
    Study

    n: not reported in source

    Comparator
    CNP-38 released from TransCon CNP
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study.

    Measurements

    Lower limit of quantification
    37 pmol/l
    CNP quantification

    Source sentences

    Summary
    Furthermore, CNP exposure for the daily CNP-39 molecule was only evident for up to 2 hours postdose (lower limit of quantification 37 pmol/l), whereas TransCon CNP gave rise to systemic exposure to CNP-38 for at least 7 days postdose.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.